Over the past few years there has been a dramatic increase in our understanding of the molecular basis of the diversity of cyclic nucleotide-specific phosphodiesterases (PDEs). These activities are encoded by multiple genes, of which over 14 have been described, with additional complexity added by alternate splicing [ 1-71. The cell-specific expression and unique properties of isoforms begs the questions as to the functional significance of this diversity and -offers the potential for the development of novel therapeutic agents.
T h e particular interest of my laboratory focuses on the PDE4A isoform family. We have been able to show that the gene for human PDE4A is localized between the genes for TYK2 and the LDL receptor in the p13.2 region on the short arm of human chromosome 19 (A. Olsen, M. Sullivan and M. D. Houslay, unpublished work). It is thus distinct from PDE4B and PDE4D, which are found on chromosomes 1 and 5 respectively [8, 9] . It is also discrete from the PDE4C gene, which we have shown is located in the p13.1 region of chrl9 and is the sole gene found between those encoding the mini G-protein Rab3A and the transcription factor JunD.
Abbreviations used: PDE, phosphodiesterase; CAT, chloramphenicol acetyltransferase; SH3 domain, Src homology domain 3.
The genes for both human PDE4A and PDE4C are extremely complex (M. Sullivan, A. Olsen and M. D. Houslay, unpublished work), having over 14 exons. However, they exhibit great similarities in organization, both with respect to each other and also with respect to those for the rat PDE4B and PDE4D [ 101 as regards conservation of intronlexon boundaries. Towards the 5' end of the genes is evidence of increasing complexity, with larger introns, a propensity to undergo 5' alternate splicing and intronic promoters controlling the expression of specific splice variants. Indeed, all PDE4 genes appear to produce multiple transcripts involving 5' domain swopping [2, 3] . For any particular PDE4 gene, those transcripts that encode active enzymes yield protein products that have identical catalytic sites and Cterminal regions but exhibit highly distinct Nterminal regions. Intriguingly, however, alternate splicing of the human PDE4A gene has also been shown to yield two products, which are enzymically inactive as the result of premature truncation within the putative catalytic region of the enzyme [Z, 111. These, however, also exhibit unique N-terminal regions as the result of 5' domain swopping. Although such species have been shown on the basis of genomic sequencing to be authentic splice variants (M. Sullivan and M. D. Houslay, unpublished work), their functional significance is not understood at present.
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Signal Termination and Compartmentalization
We have been particularly interested in trying to both define the properties and appreciate the functional role of alternately spliced PDE4A protein products. The most detailed appreciation of PDE4A products is for the rat PDE4A gene (Figure l) , for which three products have been characterized, RD1 [ 121, RPDE-6 [13, 14] and RPDE-39 [15] . However, we do have preliminary evidence, based upon cDNA library screening and immunoblotting, indicating the existence of further species [ 151. The various rat PDE4A isoforms, however, appear to show dramatically different expression patterns. Thus RD1 is exclusively found in brain [2, 12, 13, 16] , RPDE-6 is also found at highest levels in brain [13] and RPDE-39 is exclusively found in testis [15] and hepatocytes. Furthermore, analysis of brain regions shows that the expression patterns for RD1 and RPDE-6 are very different [ 13,161, perhaps suggesting distinct functional roles for these two species.
For the human PDE4A gene, however, the only active forms identified to date are PDE-46 [17] , a homologue of rat RPDE-6, and two inactive splice variant forms [18] [19] [20] . 
2el
The N-terminal splice region of PDE4A enzyme products regulates catalytic activity: modulation of V, Engineered deletion of the alternately spliced region from RD1 ( Figure 1 ) produces a 'core' PDE4A species which is common to all of the functionally active rat PDE4A isoforms [ 16,211. We have called this form MetZ6RD1 [21] and shown it to be a highly active cytosolic species when transiently expressed in transfected COS cells [16] . Using antisera able to recognize a common C-terminal epitope on PDE4A [ 161 isoforms, we have been able to quantify the relative amounts of the various PDE4A splice variants when expressed transiently in transfected COS cells and determine their relative activities . In all instances the K , values were identical, but their V,,, values, relative to that for MetZ6RD1 of 1, were 0.5, 0.15 and 0.15 for RD1, RPDE-6 and RPDE-39 respectively. Thus the Nterminal splice regions clearly can have a profound attenuating effect on the catalytic functioning of the enzyme. Consistent with this N-terminal splice region altering the conformation of such isoforms, they each show very different susceptibilities to thermal denaturation compared not only with each other but also with MetZ6RD1 [14, 21] .
The molecular basis by which these N-terminal splice regions can exert such a potent attenuating effect on enzyme catalytic functions remains to be ascertained. The potential of such regions for involvement is an additional means of dynamically regulating PDE enzyme activity through modification of the splice regions or their interaction with modulatory proteins. Possible mechanisms might include (i) the N-terminal region triggering changes in folding of the enzyme, (ii) binding of the N-terminal region to a (regulatory) site within the same PDE molecule, (iii) causing dimerization and through this the mutual modulation of the activity of the partner PDE protein, (iv) conformational changes achieved by the modification of the N-terminal domain, such as phosphorylation, and (v) binding of 'modulatory' proteins to the N-terminal splice region ( Figure 2 ).
Structure of the membrane-targeting domain of RDI
The rat brain CAMP-specific PDE4A species RD1 [12] has a unique 23-amino acid N-terminal region that arises through alternate splicing "2,131. The enzyme is entirely membrane-associ- Models through which the N-terminal splice region of PDE4 enzymes may alter catalytic activity
Deletion of the N-terminal splice region of PDE4 splice variants has been shown to lead to enhanced catalytic activity which is noted by an increase in enzyme V, , [ 14-171. We have suggested that this region alters the conformation of the active site and thus regulates catalytic activity [ 14, 161 . This N-terminal region can also confer a propensity for interaction with other proteins which may lead to membrane/cytoskeletaI association
Here we propose a number of models through which these effects may be achieved. The 'core' PDE region containing the catalytic site is denoted as a black rectangle and the splice regions as black lines. In (i) the various splice regions are suggested to act as distinct templates for the initiation of folding, leading to slight changes in structure and hence catalytic activity: in (ii) the splice region is suggested to bind to an internal site on the protein and hence alter activity: in (iii) the corollary of the previous model is that the presence of such a binding site in the 'core' PDE for the splice region would be likely to promote dimerization which would be expected to alter conformation and thus could account for the activity change: in (iv) as the splice region can modify activity, then it might be expected that posttranslational modification of this splice region, by phosphorylation for example, could alter activity as has been shown for PDE4D3 [24] : (v) the association of this domain with other proteins, such as membrane anchors or cytoskeletal proteins, may provide another route for altering conformation of this region and hence PDE activity, as indicated in studies on RDI [21] and for SH3
binding [25] . Houslay, unpublished work). The core 'soluble' species (MetZ6RD1) encoded by the PDE4A gene is, however, a totally soluble cytosolic species [ 14, 16, 21] . That membrane association is conferred upon this core 'soluble' species by the Nterminal splice region is corroborated by our observation that an in-frame chimaera, which links the splice region of RD1 to the N-terminus of the cytosolic bacterial enzyme chloramphenicol acetyltransferase (CAT), led to this chimaeric protein exhibiting membrane targeting identical with that of RD1 when it was transiently expressed in COS cells [22] .
RD1 clearly exhibits specificity as regards its membrane association. Indeed, when transiently expressed in COS cells, laser scanning confocal immunofluorescence analysis showed RD1 to be primarily associated with punctate (vesicular) structures underlying the plasma membrane as well as with the Golgi and punctate structures distributed through the cytoplasm [ 161. These observations are also consistent with biochemical fractionation studies [21] . In FTC133 and FTC236 cells, however, stably expressed RD1 was found to be associated exclusively with the Golgi (L. Pooley and M. D. Houslay, unpublished work). Furthermore, in brain, native RD1 was found associated with synaptosomal plasma membranes [16] . We consider it possible that the intracellular targeting of RDl ensues through the interaction of its N-terminal splice region with a distinct protein 'anchor'. This protein is either ubiquitously expressed in cells or forms part of a ubiquitously expressed family. The location of such an anchor appears to vary between cells. One possibility is that it is associated with vesicles that traffic between the Golgi and plasma membrane and thus its distribution could differ between cell types.
In order to define the membrane-targeting domain of RD1 we undertook a structural analysis, by 'H NMR, of a 25-mer peptide that reflects the N-terminal first 25 residues of RD1 [23] . This analysis identified (Figure 3 ) (i) an N-terminal amphipathic a-helical domain, followed by (ii) a highly mobile hinge region, then (iii) an intriguing distorted helical region of seven residues, which, unusually, contained three tryptophan residues and formed a well-structured highly hydrophobic domain, and, finally (iv) a further helical region. Having identified these distinct regions we undertook a deletion analysis, using RDl-CAT chimaeras, in order to define which of these structural features was essential Volume 24 [23] The N-terminus is at the top of the picture The various structural features are indicated These are (I) an amphipathic a-helix, (it) a highly mobile hinge region, (iii) a compact intensely hydrophobic tryptophan-rich region which forms a dis torted helical domain and is bounded by Pro'"-Trp'' together with (iv) a final helical region Only deletion of the tryptophan-rich domain caused the obliteration of membrane association [23] for membrane association. T o assay such an interaction we used [23] an in vitro transcription/ translation membrane-binding assay [22] which allowed us to synthesize in vitro the various mutant chimaeras, together with CAT, and determine which bound to membranes. We ascertained that membrane association was mediated by the distinct tryptophan-rich domain, which forms a compact distorted helical structure.
It is difficult, however, to see how this region could itself insert into membranes. We thus consider it most likely that it interacts with a membrane-bound anchoring protein which confers intracellular targeting on RD 1. That such an interaction would be hydrophobic in nature is consistent with a high-affinity association, explaining why all RD 1 was membrane-associated and also the lack of release of RDl by either repeated washing or alterations in ionic strength [14] . It might also explain why RD1 could be solubilized with concentrations of the detergent Triton X-100 well below those needed to release an integral membrane protein [14, 16, 21] . We imagine that such levels disrupt the association between RD1 and its anchoring protein.
The specific conformation of this tryptophan-rich domain is, however, apparently essential for membrane binding, as replacement of the domain with a hydrophobic 'cassette' of seven alanine residues did not reconstitute association [23] . We are currently undertaking a detailed analysis of this region by mutagenesis as well as attempting to find the anchor protein for RD1.
RPDE-6 and its human homologue PDE-46 bind to Src homology domains 3 (SH3 domains)
T h e N-terminal splice regions of both RPDE-6 and PDE-46 have a number of proline-rich regions which are of the form suggested as defining Class-I and Class-I1 SH3-binding sites [25] . SH3 domains are distinct globular structures that mediate protein-protein interactions by binding to proline-rich regions, which adopt a helical structure. These SH3 domains are found in many tyrosyl protein kinases, adaptor proteins and cytoskeletal proteins and appear to play a key role in recruiting proteins into functional complexes and for compartmentalization of signalling processes [26-301. Functional SH3 domains can be expressed as glutathione S-transferase fusion proteins and then purified on glutathione-agarose. Using these in 'pull down' assays we were able to show that RPDE-6 could bind to the SH3 domain of the tyrosyl protein kinase Src [25] . This binding was mediated by the N-terminal first 110 amino acids of RPDE-6, which contains the proline-rich motifs, as neither RPDE-39 nor MetZ6RD1 bound. However, no change in PDE activity resulted from this association. Such interaction showed a specificity, with binding for the SH3 domains of the tyrosyl protein kinase being Lyn > Fyn > Src >Abl> Crk = Lck > Csk. No binding, however, occurred to the SH3 domain of the adaptor protein Grb2, showing that RPDE-6 expression would not interfere via such means with activation of the mitogen-activated protein kinase cascade at a key step mediated by SH3-domain interaction, namely Grb2-SOS interaction [26, 30] . Interestingly, however, in the case of Crk, Lck and Csk, although binding was weak, the activity of the immobilized RPDE-6 was found to be markedly diminished. Indeed, we have recently been able to show (J. O'Connell and M. D. Houslay, unpublished work) that RPDE-6 can bind strongly to the SH3 domain of the cytoskeletal protein fodrin, leading to the cessation of PDE activity.
Thus binding of RPDE-6 to SH3 domains might serve to: (i) immobilize PDE activity in the vicinity of regulatory protein, such as a tyrosyl protein kinase, the signalling function of which may be influenced through protein kinase A action, and thus recruitment of a specific PDE could serve a regulatory role; (ii) provide a means of regulating the activity of a specifically localized PDE; (iii) provide a latent source of PDE the activity of which is expressed upon release; (iv) together with the targeted localization of protein kinase A, which binds to specific anchoring proteins (AKAPs) [31, 32] , provide a molecular basis for the generation and control of 'compartmentalized' CAMP signals within cells.
Using the SH3 domain of Fyn in 'pull down' assays we screened high-speed supernatant fractions from a variety of rat tissues (J. O'Connell and M. D. Houslay, unpublished work). However, only with brain extracts did significant PDE activity become associated with the SH3 fusion protein. Nevertheless, all of the associated activity was shown to be of the rolipram-inhibitable PDE4 variety, indicating that the propensity to interact with SH3 domains may be an exclusive property of this enzyme family. Analysing such associated material with generic PDE4 isoform subfamily-specific antisera, we were able to show that not only PDE4A bound to the SH3 domain but PDE4D was also associated. This shows a dramatic specificity, as brain contains a huge array of different PDE forms as well as all classes of PDE4 forms, including PDE4B [33] and PDE4C [34] isoforms. T h e PDE4A found associated with the SH3 domain of Fyn in 'pull down' assays from rat brain cytosol was shown to be due exclusively to RPDE-6. For PDE4D, however, a single species was identified. This migrated in an identical fashion with the human PDE4D4 isoform which, intriguingly, has a proline-rich N-terminal splice region. Indeed, expressing this isoform in COS cells allowed us to show that it too can bind to SH3 domains.
Expression of PDE4A splice variants
PDE4A splice variants are differentially expressed in various cell types which is consistent with them having distinct functional roles [2, [12] [13] [14] [15] [16] 331 . The factors that control PDE4A splice variant expression are ill-understood. However, Conti and co-workers [3, 10, 35, 36] have provided good evidence for the existence of intronic promoters, which determine the expression of certain PDE4D splice variants. In this regard, chronic elevation of cAMP levels can elicit an adaptive response by exerting a profound effect upon PDE4 expression patterns [37] . In the case of the PDE4A forms, chronic treatment of human monocyte-like cell lines leads to the up-regulation of PDE-46 (human homologue of RPDE-6), PDE4B and, in some cells, PDE4D [37-391. In contrast, such treatment (S. Ergodan and M. D. Houslay, unpublished work) of Jurkat T-cells actually down-regulated a novel PDE4A splice variant and caused the induction of PDE4D1 and PDE4D2 isoforms.
T h e functional consequences of altering the balance of the predominant PDE4 isoforms in various cell types has yet to be ascertained. Intriguingly, however, a paradigm for such a scenario may be provided by studies on thymocytes [40] . In these cells the dominant PDE activity is supplied by the PDE4 isoforms. However, small increases in cGMP concentration leads to such a profound activation of the PDE2 activity in these cells that the activity of this isoform then predominates. It is possible that CAMP metabolism in thymocytes switches from the control of PDE4 to that of PDE2 depending on the levels of cGMP in these cells. This might occur upon activation of guanylate cyclase in these cells by stimulation of NO production in either these cells or cells nearby. This latter event might occur during recruitment or processing phenomena when the functioning of thymocytes can be expected to change profoundly.
Although many instances of changes in PDE activity in disease states such as asthma, leukaemia and diabetes have been reported [3, 6, 7] , only now are the reagents available to determine which isoforms are changed and from there to dissect out the functional consequences.
Conclusion
The PDE4A gene can be considered as encoding a core 'soluble' highly active protein to which distinct N-terminal regions are added by alternate splicing. It is highly likely that over six splice variants of the human PDE4A exist, and it will be extremely interesting to define the basis for their expression and functional significance. From what we know already, the N-terminal domains of these species apparently regulate activity, thermostability and the propensity to interact with other specific proteins, which can lead to unique intracellular targeting and changes in activity. An understanding of these enzymes may aid our appreciation of the fundamentals of the regulation of cAMP signalling within cells and the changes that occur in disease states and may also provide us with new diagnostic aids and therapeutics.
It is perhaps a salutary observation that, although the CAMP signalling system has provided the paradigm for the signalling field, it is only now that the true complexity of the proteins involved in mediating this response are becoming apparent. Far from there being a single source of production, degradation and recognition, there are now over eight isoforms of adenylate cyclase (see e.g. . This allows the CAMP signalling system to be tailored in a highly cellspecific fashion. Through the selection of appropriate partners, one can: (i) target components within the three-dimensional matrix of the cell; (ii) set the response of the system such that, under resting conditions, the futile cycling of CAMP is either low, in which case PDE regulation will primarily affect receptor-adenylate cyclase-driven responses, or high such that changes in PDE activity can modulate or even trigger cellular events by dramatically manipulating CAMP levels; (iii) possibly serve a central 'integrating' role in cellular 'learning' processes by providing adenylate cyclase and PDE isoforms which can couple to signals emanating from every known signalling pathway. Thus the CAMP signalling system may actually provide the 'core' machinery for integrating signalling within the cell. Therefore an appreciation of the molecular details of the enzymes involved and the aberrations that occur in disease states may be of profound significance. 
Introduction
Intracellular responses to many hormones and neurotransmitters are mediated by signal-transduction pathways, which alter the phosphorylation state of key regulatory proteins [l] . Protein phosphorylation is a reversible process involving two classes of signalling enzymes: protein kinases, which catalyse the phospho-transfer reaction, and phosphoprotein phosphatases, which catalyse the dephosphorylation step [ 1,2].
T h e activity of both enzyme classes is tightly regulated and responds to fluctuations in diffusible second messengers such as Ca2+, phospholipid and cAMP [2] . T h e predominant effect of cAMP is to activate the CAMP-dependent protein kinase (PKA), which modifies serine and threonine residues on substrate proteins [3] . Since PKA has a broad substrate specificity and is present in relatively high intracellular concentrations [4] , it is critical to restrict the activity of the enzyme and its substrate availability. One way to accomplish this is by localizing it to specific cellular compartments [S-71. Compartmentalization of the kinase seems to represent a regulatory Abbreviations used: PKA, protein kinase A.; RII, regulatory subunit of type-I1 PKA; AKAP, A-kinase anchoring protein; MAP, microtubule-associated protein; PKC, protein kinase C; AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid. *To whom correspondence should be addressed. mechanism that may increase the selectivity and intensity of a CAMP-mediated hormonal response. In order to facilitate this process, up to 75% of type-I1 PKA is targeted through association of the regulatory subunit (RII) with Akinase anchoring proteins (AKAPs) (reviewed by Rubin [7] ). In addition, there is now some indication that the type-I PKA is also compartmentalized [8, 9] . In recent years, numerous AKAPs have been identified that target PKA to a variety of subcellular locations [ 10-161. These proteins represent a growing family of signalling molecules that contain a conserved PKA-binding motif, which function to localize the kinase, thereby favouring access to certain substrates [17] . In this paper we will discuss the structure and function of PKA-AKAP interactions.
AKAPs
Initially, anchoring proteins were identified by Rubin and colleagues [18] as contaminating proteins that copurified with RII after affinity chromatography on CAMP-Sepharose; however, detailed study of AKAPs was made possible by the original observation of Lohmann [ 191 that many, if not all, of these associated proteins retain their ability to bind RII after they have been immobilized to nitrocellulose or similar solid-phase supports. As a result, the standard technique for detecting AKAPs is an overlay method, which is essentially a modification of the Volume 24 
